Singapore markets closed

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
34.26-0.57 (-1.64%)
At close: 04:00PM EST
34.25 -0.01 (-0.03%)
After hours: 06:09PM EST
Full screen
Trade prices are not sourced from all markets
Previous close34.83
Open34.75
Bid34.25 x 800
Ask34.38 x 800
Day's range34.26 - 36.02
52-week range30.12 - 58.35
Volume500,529
Avg. volume261,711
Market cap2.004B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

    MONROVIA, Calif., January 11, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated clinical development and research milestones.

  • Business Wire

    Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

    MONROVIA, Calif., January 06, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.

  • Business Wire

    Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

    MONROVIA, Calif., December 12, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be presented by Krish Patel, M.D., Director of the Lymphoma Program at Swedish Cancer Institute, in a poste